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Fatigue is often reported in stroke patients. However, it is still unclear if fatigue in stroke
patients is more prominent, more frequent or more “typical” than in patients with mul-
tiple sclerosis (MS) and if the pathophysiology differs between these two populations.
The purpose of this study was to compare motor fatigue and fatigue-induced changes in
kinematic gait parameters between stroke patients, MS patients, and healthy persons.
Gait parameters at the beginning and end of a treadmill walking test were assessed in 10
stroke patients, 40 MS patients, and 20 healthy subjects. The recently developed Fatigue
index Kliniken Schmieder (FKS) based on change of the movement’s attractor and its vari-
ability was used to measure motor fatigue. Six stroke patients had a pathological FKS.
The FKS (indicating the level of motor fatigue) in stroke patients was similar compared to
MS patients. Stroke patients had smaller step length, step height and greater step width,
circumduction with the right and left leg, and greater sway compared to the other groups
at the beginning and at the end of test. A severe walking impairment in stroke patients
does not necessarily cause a pathological FKS indicating motor fatigue. Moreover, the FKS
can be used as a measure of motor fatigue in stroke and MS and may also be applicable
to other diseases.
Keywords: multiple sclerosis, stroke, motor fatigue, gait analysis, attractor, fatigue index, questionnaire assess-
ment, physical performance
INTRODUCTION
Fatigue is a frequent symptom in many neurologic diseases (1)
and especially common and disabling in patients with multi-
ple sclerosis (MS) (2, 3). Moreover, fatigue is often the reason
for early retirement and hence represents a high economic bur-
den (4). Despite the high prevalence of fatigue in MS of up to
83% (1), its pathophysiology is largely unknown (5, 6). Nonethe-
less, several pathophysiological pathways have been proposed:
demyelinisation and axonal injury may cause “electric failure” (7);
immunological and inflammatory factors such as cytokines may
hamper neuronal processing (8); hormonal dysregulation may
be caused by failed cortico-hypothalamic loops (9); and reorga-
nization and compensation might add to the ineffectiveness of
cerebral control and cause fatigue (10). Moreover, fatigue may
be secondary to conditions including depression, sleep disorders,
physical deconditioning, anemia, or side effects of medication
(3, 11, 12).
In the last decade, reports of fatigue in neurological conditions
other than MS, such as for instance stroke, have become more
frequent (13, 14), and the prevalence of fatigue in patients after
stroke ranges from 36 to 77% (1). Fatigue is a common and debil-
itating symptom even in patients with good recovery after stroke
(15). Patients’ level of fatigue does not change over time (16) and
baseline fatigue immediately after a stroke predicts fatigue out-
come (17). Staub and Bogousslavsky (18) suspected that primary
poststroke fatigue may be caused by minor attentional deficits due
to the interruption of neural networks, such as the reticular acti-
vating system. Patients use different strategies and coping styles to
deal with poststroke fatigue (19). In addition, poststroke fatigue
appears to be an independent determinant of not being able to
resume paid work following stroke (20).
Currently, there are no widely accepted standard definitions
or accepted standardized methods and instruments for assessing
fatigue (1). Moreover, fatigue is understood as a multidimensional
phenomenon with different aspects including a complex interplay
between the underlying disease process, peripheral, and central
control systems, as well as environmental factors (21). Its multidi-
mensionality complicates the assessment of fatigue in neurological
disorders. Kluger et al. (1) proposed a new taxonomy for fatigue in
neurologic diseases and suggested differentiating between fatigue
as subjective sensation and fatigability as an objective change in
performances. Here, we distinguish between cognitive and motor
components, which can occur in isolation or in combination.
Commonly, the subjective perception of fatigue is assessed using
questionnaires (22), and the measurement properties of fatigue
questionnaires in MS have previously been evaluated (23). The
most frequently used instruments for measuring fatigue in MS
patients are the Fatigue Severity Scale (FSS) (24), the Fatigue
Assessment Instrument (FAI) (25), the Fatigue Impact Scale (FIS)
(2), the Modified Fatigue Impact Scale (MFIS) (26), the Fatigue
www.frontiersin.org December 2014 | Volume 5 | Article 279 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sehle et al. Objective assessment of motor fatigue
Scale for Motor and Cognitive Functions (FSMC) (27), and the
Würzburg Fatigue Inventory in Multiple Sclerosis (WEIMuS) (28).
Despite the reported prevalence of fatigue in MS and stroke, few
studies used the same tools for assessing fatigue in these two
conditions (compare also Lukoschek et al., in this special issue)
(23). Moreover, in contrast to MS, there are no fatigue ques-
tionnaires that have been developed specifically for measuring
fatigue after stroke (29). Often, the following instruments are used:
the FSS (24), the Short-form 36/12 vitality questions (30), the
Fatigue Assessment Scale (FAS) (31), and the Multidimensional
Fatigue Symptom Inventory (MFSI) (14, 32). Overall, fatigue may
be assessed quickly using fatigue questionnaires. However, these
questionnaires are based on patients’ self-assessments and may be
distorted (overestimation or underestimation) due to an inaccu-
rate self-perception (33). Moreover, fatigue questionnaires capture
patients’ general condition during a particular time period (33)
and fatigue may also be quickly clinically assessed by physicians
or physiotherapists. However, clinical experience suggests that an
accurate identification of fatigue and non-fatigue depends on the
experience of the therapists and physicians, and in some cases
a clear diagnosis of fatigue is difficult. Especially, comorbidities
(depression, sleep disorders, physical deconditioning, anemia, or
side effects of medication) may cause similar symptoms (33). In
these cases, the objective instrument can be extremely helpful for
measuring fatigue. A correct diagnosis of fatigue is not only impor-
tant to define optimal treatment but also when it is used as criterion
for early retirement.
In the current study, we focused on the motor dimension of
fatigability (here, we used the term motor fatigue as a synonym)
in stroke and MS patients. The motor dimension of fatigability
has previously been assessed in lower limbs using dynamometry
in isometric contractions, sustained maximal contractions, repet-
itive maximal contractions, and walking as far as 500 m (34, 35)
and in upper limbs using static and dynamic contraction tests
(36–38) in MS patients. Hence, overall maximal force appeared
to decrease either during repeated maximal contraction or dur-
ing sustained contraction in MS patients. Furthermore, Severijns
et al. (38) observed differences in sustained maximal hand grip
contraction but not in dynamic contraction between healthy sub-
jects and MS patients with high EDSS (≥6) (38). Schwid et al.
(35) proposed that motor fatigue can be measured as a decline
in strength during sustained muscle contractions (35). Similarly,
Greim et al. (36) proposed that decreases in strength of max-
imal repetitive muscle contraction and/or decrease of walking
speed can be used to measure motor fatigue objectively (36). Post-
stroke motor fatigue has previously been assessed in a few studies
in upper and lower limbs using transcranial magnetic stimula-
tion, dynamometry, and/or electromyography during the maximal
voluntary contraction (MVC), sustained isometric contraction,
submaximal contraction, and repetitive eccentric–concentric con-
traction (39–41). Knorr et al. (40) showed that during fatigue
the silent period duration increased significantly in both upper
limbs, whereas the motor evoked potential amplitude significantly
increased only in the non-paretic limb (40). After fatigue, the
reductions in the M wave, twitch peak torque, and MVC peak
torque were observed in both limbs. Furthermore, the reduc-
tion in voluntary activation was greater in the paretic than in
the non-paretic limb (40). Another study concluded that a reduc-
tion in work in high-intensity dynamic muscle activity may not
be associated with a reduction in mean power frequency (39).
Hu et al. (41) suggested that for identifying fatigue associated
with neuromuscular transmission failure, the motor unit fir-
ing parameters firing rate, minimum inter-pulse interval, and
maximum oscillation were more sensitive than the mean power
frequency (41).
We recently developed the Fatigue index Kliniken Schmieder
(FKS) as an objective tool for assessing motor fatigue in MS based
on gait changes in a walking test on the treadmill (33). In this study,
the subjects walked on a treadmill under different conditions: in
a normal rested state and in an exhausted state or after 60-min
walking. We measured the changes in acceleration patterns and
acceleration variability of the feet during the walking test at the
beginning and at the end of the walking test in MS patients and
healthy subjects. Furthermore, in this study, we developed the FKS
that is composed of these two components and which makes the
distinction between fatigue and non-fatigue. The FKS described
the changes in acceleration patterns and acceleration variability
during the walking test on the individual level. The advantage of
a walking test is that the entire musculature, especially the major
muscle groups are required. This task is daily task-oriented and
represents a complex movement with many degrees of freedom.
In contrast to fatigue questionnaires, this test captures the current
state of motor fatigue.
To date, it is still unclear if fatigue is specific to MS or at least to
inflammatory disease or if it is an unspecific reaction of the brain
after any kind of brain injury (1). The inflammatory etiology is
supported by the fact that other inflammatory diseases such as
sarcoidosis or cerebral vasculitis can be accompanied by serious
fatigue. In stroke, fatigue may be related to reorganization or inef-
ficient/suboptimal fiber tract connections or compensatory effort.
Although we were not able to investigate different pathophysiolog-
ical mechanisms directly by surrogate markers such as cytokines or
tumor necrosis factor alpha or by different cerebral activation pat-
terns, the intention of our study was to compare motor fatigue in
patients with stroke and MS. This should facilitate better under-
standing limitations and needs of patients and more accurately
define their goals for instance in rehabilitation. Therefore, the aim
of our study was to investigate if the amount of change of the gait
pattern during an exhausting physical task differs between stroke
and MS patients. After propagating the test for identifying motor
fatigue in MS (33), this investigation also should clarify if this
test and the FKS are feasible for stroke patients and that a severe
walking impairment in stroke patients does not necessarily cause a
pathological FKS. Data of patients after stroke were collected and
compared with previously published data (33) on 40 patients with
MS and 20 healthy subjects.
MATERIALS AND METHODS
SUBJECTS
Ten patients who were admitted to a neurological rehabilitation
clinic after stroke, met the inclusion criteria, and volunteered to
participate between March and October 2012 were included in this
study. Inclusion criteria were central hemiparesis affecting the leg,
reduced walking capacity, and the ability to walk on a treadmill
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without aids or assistance. All stroke patients were chronic (time
since the onset of stroke> 12 months). Hemiparesis was left sided
in four patients and right sided in six patients. Eight patients had a
proportional hemiparesis affecting arm and leg, and two patients
were more affected in their legs. Three patients had a haemor-
rhagic infarction and seven patients an ischemic infarction. One
infarct was located in the brainstem, one in the anterior cerebral
artery (ACA), and eight in the middle cerebral artery (MCA). Two
MCA infarcts showed additional involvement of the ACA.
Data from our previous study (33) involving 20 healthy sub-
jects and 40 patients with definite MS according to the McDonald
criteria (42) were used in this study. MS patients and control sub-
jects were recruited between October 2011 and July 2012. The
MS patients were admitted to a neurological rehabilitation clinic.
Inclusion criterion for MS patients was the ability to walk on a
treadmill without aids or assistance. There were no limitations
regarding the disease course and disability levels. Subjects were
excluded from the study if they had relapses within the preceding
three months or received Fampyra® (Fampridin; Biogen Idec Inc.,
225 Binney Street, Cambridge, MA 02142). Healthy subjects were
recruited from the local population and from clinic staff. Healthy
subjects were excluded if they had any neurological or orthopedic
disorders. In the previous study, the MS patients were classified
into two groups based on the FKS: patients with a FKS> 4 were
categorized as having motor fatigue (MS-F), and patients with a
FKS≤ 4 were categorized as having no motor fatigue (MS-NF).
According to these criteria, 29 MS patients were in the fatigue
group and 11 MS patients in the non-fatigue group.
All participants provided informed written consent prior to
participation. The study protocol was approved by the Univer-
sity Ethics Committee and conducted in accordance with the
Declaration of Helsinki.
QUESTIONNAIRES
At admission to the study, all subjects answered the Beck Depres-
sion Inventory II (BDI-II) to assess the level of subclinical depres-
sion (43). Self-reported physical function was assessed by patients
using the physical functioning 10 subscale of the Short-form 36
(PF-10; SF-36) and four vitality questions of the SF-36 (44, 45).
Vitality questions from the SF-36 have previously been suggested
as measures of fatigue (46). These two assessments allowed for
comparison of physical impairments and complaints about fatigue
between groups.
EXPERIMENTAL PROCEDURE
An exercise task and a functional test were carried out on two dif-
ferent days for each stroke patient. The exercise task included a
walking test on a treadmill: patients walked either until they felt
physically exhausted [17 – very hard, on the Borg scale (47)]; or for
up to 60 min at 10% above their preferred speed or a maximum
speed of 5 km/h on a level treadmill. The preferred walking speed
was determined at an initial exam where each subject walked on the
treadmill to familiarize them with the set-up. An important crite-
rion was that the subjects were able to walk on a treadmill without
aids or assistance. The walking speed was limited to a maximum of
5 km/h so that subjects stayed within a comfortable walking speed
(48). The treadmill speed was kept constant throughout the test.
The participants were repeatedly asked to rate their exhaustion on
a Borg scale. The walking test was stopped 1 min after the patient
reached 17 on the Borg scale or after 60-min walking on the tread-
mill. Kinematic gait data were measured for 1 min at the beginning
of the walking test (t1) and for 1 min after reaching 17 on the Borg
scale or for the final minute of 60 min (t2).
The functional test consisted of a 6-min walk test (6MWT)
(49). The 6MWT is often used in clinical practice and has been
frequently used for measuring the response to therapeutic inter-
ventions in various diseases. Heart rate was measured prior to
and at the end of the walking test, and lactate concentration
was measured prior to and immediately after walking. We used
the 4 mmol/L lactate threshold originally described by Mader
et al. (50).
TECHNICAL EQUIPMENT
The AS200 system (80 Hz; LUKOtronic, Lutz Mechatronic Tech-
nology e.U., Innsbruck, Austria) was used to record the gait data.
This system consists of a three line-scanning camera system and
10 active markers attached bilaterally to the subjects’ body: cen-
tered on the margo medialis; the highest point of the ilium; the
posterior aspect of the knee; on the shoes on top of the calcaneus
and on the rod attached at the level of the ankle.
Videos were recorded with a HD digital camera synchronized
with the motion analysis system (Exilim EX-F1, digital camera,
Casio Computer Co. Ltd., Tokyo, Japan). Heart rate was captured
using a chest strap and a gage (Garmin Forerunner 305, Garmin
Ltd., KS, USA). Lactate levels in the blood were detected using a
lactate analyzer and lactate strips (Arkray Lactate Pro LT-17810,
Kyoto, Japan).
CALCULATION OF THE FATIGUE INDEX KLINIKEN SCHMIEDER
For each stroke patient, the change in the movement pattern
described by the attractor (δM ) and change in movement vari-
ability (δD) of the acceleration of the feet between t 1 and t 2 were
calculated (Figures 1 and 2A,B). This new method has recently
been described in detail by Vieten et al. (51) and used to detect
motor fatigue in patients with MS (33). The changes in move-
ment acceleration patterns and variability were used as indicators
of motor fatigue. It is well known that human walking in the
absence of disturbances is characterized by a stable movement
pattern and consistent movement control. We kept the walking sit-
uation unchanged throughout the walking test, and hence changes
in attractor and movement variability indicated an alteration of the
gait mechanism, which by ruling out other reasons, we identified
as acute motor fatigue. The calculation of FKS was based on both
feet. The FKS was defined as the changes in δM and δD between
the beginning and the end of walking (51) and represented as
δF = δM · δD
The FKS was calculated for each stroke patient. These patients were
then classified according to the FKS in a fatigue and non-fatigue
group. This method allows analyzing fatigue on the individual
patient level and on the group level. Based on FKS, stroke patients
with FKS≤ 4 were identified as having no motor fatigue (stroke-
NF) and stroke patients with FKS> 4 were identified as having
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FIGURE 1 |Two-dimensional graph of the acceleration data of a
subject’s left foot for one minute (A) at the beginning and (B) at the
end of the walking test for one stroke patient with fatigue.
motor fatigue (stroke-F). The FKS cut-off of 4 was calculated in
our previous study in the following order: first, using the group
medians calculated using traditional methods (neurologist rating)
to find the threshold between normal and fatigue (33). Second, the
FKS of healthy individuals was used as a benchmark test. Third, all
subjects were classified according to the FKS values into the fatigue
and the non-fatigue groups.
CONVENTIONAL GAIT ANALYSIS
Spatial parameters were calculated: step length, step width, step
height, maximum circumduction of the right and left leg, and
medio-lateral sway of the upper body were calculated using three-
dimensional co-ordinates of the active markers. This analysis
allowed comparisons between different groups on the group level.
EVALUATION OF THE VIDEO RECORDINGS
The subjects’ movement patterns were recorded on videos
captured during t 1 and t 2 from the side and from the back. Videos
FIGURE 2 |Two-dimensional graph of the acceleration data of a
subject’s left foot for one minute (A) at the beginning and (B) at the
end of the walking test for one stroke patient without fatigue.
were evaluated by two experienced physiotherapists from the reha-
bilitation clinic. The order of the videos was randomized, and
thus the physiotherapists did not know which video had been cap-
tured at the beginning and which at the end of walking test when
attempting to correctly assign the videos to the corresponding time
period. The physiotherapists did not evaluate the details regarding
the modality of movement.
STATISTICAL ANALYSIS
Data of stroke patients were compared to those of MS patients and
healthy control subjects (33). All statistical tests were performed
using StatFree Version 8.0.0.9 (VietenDynamics, University of
Konstanz, Germany) and Stata Version 11.0 (StatCorp LP, Col-
lege Station, TX, USA). Differences in non-normally distributed
parameters between groups were detected using Kruskal–Wallis
test with Mann–Whitney U test as post hoc tests. For categori-
cal variables, we used the χ2-test. Pearson correlation coefficients
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were used to detect significant associations between the changes
in the movement pattern and changes in movement variability as
well as between FKS and the results of BDI-II. The significance
level for all statistical tests was set a priori to.05.
RESULTS
DIFFERENCES BETWEEN STROKE PATIENTS, MS PATIENTS, AND
HEALTHY SUBJECTS
Table 1 presents descriptive characteristics for stroke patients, MS,
and healthy subjects. Significant differences between stroke and
MS patients were found for sex, age, height, and mass. Further-
more, the PF-10 and vitality score of the SF-36 differed signifi-
cantly between the stroke and MS groups with a higher physical
impairment and higher vitality level in stroke patients (p< 0.04
and p< 0.02, respectively). In contrast, no significant differences
were detected between stroke patients and healthy subjects with
the exception of age.
Based on the BDI-II questionnaire, one patient was affected by
minimal depression and one patient was affected by slight depres-
sion in the stroke group. All other patients with stroke were not
affected by depression. Moreover, 65% of MS patients and 15% of
healthy subjects were affected by depression.
PHYSICAL PERFORMANCE IN STROKE PATIENTS COMPARED WITH MS
PATIENTS AND HEALTHY SUBJECTS
Table 2 shows the physical performance in three groups. The
stroke patients walked significantly slower than the healthy sub-
jects (p< 0.001) and a shorter distance than MS patients and
Table 1 | Mean (1 standard deviation) characteristics of participants.
Characteristic Stroke MS Healthy subjects p-value
Sex male/female 7/3 13/27 9/11 0.03a
Age 51.6 (8.3) 45.9 (7.0) 43.1 (8.6) 0.03a
0.01b
Height (cm) 177.2 (7.7) 171.4 (10.7) 173.4 (8.4) 0.04a
Mass (kg) 84.5 (16.5) 74.1 (15.6) 80.4 (21.3) 0.04a
SF-36, PF-10 16.3 (4.8) 21.0 (4.3) Not collected 0.04a
SF-36, vitality 15.8 (2.2) 11.1 (3.5) Not collected 0.02a
BDI-II (% of patients with depression) 20.0 65 15.0 0.02a
EDSS Not applicable 3.4 (1.3) Not applicable
Disease duration (years) 8.3 (7.9) 10.8 (7.2) Not applicable
MS, MS patients; SF-36, PF-10, 10 items of the physical functioning (ranging from 10 to 30, where low values indicate strong impairment, high values low impairment);
SF-36, vitality scale, four items each ranging from 1 (low vitality/high fatigue) and to six (high vitality/low fatigue); BDI-II, Beck Depression Inventory II; EDSS, Extended
Disability Status Scale ranging from 0 (no symptoms) to 10 (death through MS).
aSignificantly different between stroke and MS.
bSignificantly different between stroke and healthy subjects. Only the significant differences are indicated.
Table 2 | Mean (1 standard deviation) gait and physiological parameters of the walking test.
Parameters Stroke MS Healthy subjects p-value p-value
Kruskal–Wallis test Post hoc test
Walking distance (km) 1.9 (0.9) 2.5 (1.6) 5.3 (0.3) 0.001 0.001a
Walking speed (km/h) 2.2 (0.8) 3.4 (1.4) 5.0 (0.0) 0.001 0.01b
0.001a
6MWT (km) 0.30 (0.11) 0.51 (0.10) 0.68 (0.10) 0.001 0.001b
0.001a
Lactate (mmol/L)
t1 0.7 (0.6) 1.1 (0.6) 0.8 (0.6) 0.04 0.02b
t2 0.2 (0.4) 0.6 (0.5) 0.6 (0.6)
Heart rate (bpm)
t1 70.0 (10.8) 79.2 (11.0) 79.4 (20.7)
t2 99.9 (13.2) 104.8 (16.8) 108.8 (20.8)
Borg scale 14.0 (1.7) 16.0 (2.6) 10.0 (2.5) 0.001 0.001b
0.001a
Stroke, stroke patients; MS, MS patients; 6MWT, 6-min walk test.
aSignificantly different between stroke and MS.
bSignificantly different between stroke and healthy subjects.
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healthy persons (p< 0.01) in the walking test on the treadmill.
Walking distance ranged from 1.0 to 3.4 km and walking speed
ranged from 1.0 to 3.3 km/h in stroke patients. In MS patients,
walking distance ranged from 0.2 to 5.6 km and walking speed
ranged from 0.9 to 5.0 km/h. In healthy subjects, walking distance
ranged from 5.0 to 6.0 km and walking speed was 5 km/h. The
stated speed refers to the speed with which subjects walked on
the treadmill after the familiarization phase and in which all data
were collected. Some subjects walked slower in the familiarization
phase and then they increased their speed. The important crite-
rion was that the subjects do not walk over 60 min in the test. In
the 6MWT, stroke patients walked a significantly shorter distance
than the other groups (p< 0.001).
All subjects remained below the aerobic-anaerobic threshold
(lactate concentration below 4 mmol/L) during the walking test
and had a heart rate below the maximal heart rate. At the end of
the test, the level of exertion on the Borg scale was significantly
lower in stroke patients than in MS patients (p< 0.001). In con-
trast, stroke patients had greater levels of exertion than healthy
subjects (p< 0.001).
CONVENTIONAL GAIT ANALYSIS IN STROKE PATIENTS COMPARED
WITH MS PATIENTS AND HEALTHY SUBJECTS
Significant group differences in gait parameters were observed at
t 1 and at t 2 (p< 0.001). The results of the post hoc tests revealed
that stroke patients had shorter step lengths and greater step widths
than the other groups both at t 1 and t 2 (p< 0.001). Furthermore,
the stroke patients had lower step height than the MS patients and
healthy persons at t 1 and t 2 (p< 0.001). Circumduction with the
right and left legs as well as the sway were significantly greater in
the stroke group than in the other groups at t 1 and t 2 (p< 0.009).
VIDEO ANALYSIS
One physiotherapist correctly classified 6 of 20 (30%) and the
other physiotherapist 8 of 20 (40%) videos of stroke patients indi-
cating that they were correct just by chance and did not recognize
increasing gait abnormality at the end compared to the beginning
of the walking test. In contrast, the physiotherapists classified most
of the videos correctly in the MS group 68 of 80 (85%) and 64 of
80 (80%), respectively. In healthy subjects, the physiotherapists
properly classified 26 of 40 (65%) and 34 of 40 (85%) videos,
respectively.
FATIGUE INDEX KLINIKEN SCHMIEDER COMPARISON BETWEEN
GROUPS
Based on the FKS scores, six stroke patients were classified into the
fatigue group (stroke-F) and four patients into the non-fatigue
group (stroke-NF). The FKS in the stroke-F group ranged from
5.3 to 15.3 (δM: 4.1–9.3; δD: 1.1–1.9) and in the stroke-NF group
from 2.2 to 3.2 (δM: 1.8–3.6; δD: 0.6–1.4). The FKS in the MS-F
group ranged from 4.2 to 125 (δM: 2.8–30.4; δD: 0.9–4.1) and in
the MS-NF group from 0.5 to 3.4 (δM: 1.0–3.6; δD: 0.4–1.0). The
FKS in the healthy subjects ranged from 0.3 to 3.9 (δM: 0.6–4.3;
δD: 0.3–1.5) (Figure 3). The FKS differed significantly between
stroke patients and healthy persons (p< 0.001) but not between
stroke and MS patients (p= 0.44). In the subgroups, the FKS dif-
fered significantly between the stroke-F and the stroke-NF, MS-NF,
FIGURE 3 | Boxplot for FKS values in all groups.
FIGURE 4 | Scatterplot between changes in movement pattern and
movement variability.
and healthy groups (p< 0.01). Mean FKS in the stroke-F group
was smaller than that in the MS-F group, but this difference did
not reach statistical significance (8.7 versus 17.5; p= 0.18). In
all groups, subjects with greater changes in movement patterns
also showed greater changes in movement variability (r = 0.66,
p< 0.001) (Figure 4). The differences in changes in movement
patterns and changes in movement variability between groups
corresponded to the differences in FKS between groups. Further-
more, FKS did not correlate significantly with the results of BDI-II
(r = 0.27, p< 0.09).
DISCUSSION
The purpose of this study was to compare motor fatigue in stroke
and MS patients by analyzing changes in movement patterns and
their variability. In this pilot study, we observed no significant dif-
ference in FKS values between stroke and MS patients as well as
in their subgroups: between stroke patients with fatigue symptom
and MS patients with fatigue symptom. Hence, fatigue induced
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similar changes in the movement patterns and variability in both
patient groups. Furthermore, the results of our study showed
that the FKS can also be used in stroke patients for objectively
measuring motor fatigue.
We intended to verify that severe walking impairment in stroke
patients does not cause a pathological FKS. During the walking
test on the treadmill, stroke patients rated their fatigue on the
Borg scale significantly lower than the MS patients. Interestingly,
despite lower perception of fatigue on the Borg scale, the stroke
patients had greater physical impairment. All stroke patients had
a hemiparesis affecting the leg. A higher level of impairment was
observed using kinematic gait analysis, PF-10 of SF-36, and phys-
ical performance. Using conventional kinematic gait analysis of a
few single stride cycles, we observed very clear differences in all gait
parameters between the stroke patients and the other groups at t 1
and t 2. Generally, the stroke patients showed smaller step length,
step height and greater step width, circumduction with the right
and left leg, and greater sway compared to MS patients and healthy
subjects. These results are in agreement with other studies (52, 53).
The reduced step length and greater step width in stroke patients
indicate an unsteady gait and the attempt to improve their stabil-
ity to avoid falling while walking. The altered gait pattern already
present at the beginning of the walking test on the treadmill, com-
pared to the other groups, is presumably caused by the hemiparesis
in this patient group. The reduction of walking speed and walk-
ing distance in stroke patients compared to the other groups as
measured in our study are well established (53, 54).
Although stroke patients had higher physical impairment on
PF-10 of SF-36 than MS patients, they showed greater vitality
scores on the SF-36 than MS patients. These results point toward
a conceptual and pathophysiological difference between impair-
ment and fatigue. While it can be disputed whether or not fatigue
should be rated as impairment, the neurological exam or the PF-10
of SF-36 do not assess fatigue.
The origin of peripheral or muscle fatigue is outside the cen-
tral nervous system (CNS). For example, the peripheral fatigue
can be caused by an increased blood lactate accumulation and
hydrogen ions, accumulation of ammonia, loss of water, an accu-
mulation of Pi (inorganic phosphate), and an accumulation of H+
ions in the sarcoplasm (55). There are several objective methods
for measuring peripheral fatigue. Among others, muscle fatigue
can be detected using surface electromyography (sEMG) and
mechanomyography (MMG) (56). Previous studies investigated
manifestations of fatigue in prolonged activities involving repet-
itive low force work tasks. In contrast to our study, they used
task duration of more than 1 h with an intensity of 20% max-
imum voluntary contraction in an isolated movement with few
active muscles (57). For example, they measured fatigue using
electromyography of a descending part of the trapezius muscle.
In our study, walking is a complex movement with involvement
of many muscle groups and several degrees of freedom. Based
on the results of our previous studies, we expected that patients
with fatigue would be exhausted in less than 60 min (33, 58).
One of the most popular cost-efficient and quick measurement
of muscle fatigue is the analysis of blood lactate during exhaustive
exercises. We used this method in our study. All subjects walked
on the treadmill without reaching their lactate threshold, which
reflects the rate at which a person can work aerobically without
accumulation of acid substances associated with muscular fatigue
(59). However, some patients have reached exhaustion as these
patients reported 17 (very hard) on the Borg scale and/or the
FKS was >4. None of the healthy persons reached exhaustion in
the walking test determined using the Borg scale and the FKS.
Hence, it seems unlikely that motor fatigue was not associated
with muscular fatigue.
A strong relationship between depression and fatigue has been
described in both patient groups (3, 18). Moreover, depression is
considered one of the most confounding factors associated with
fatigue; it can be hard to disentangle depression and fatigue in a
patient. In the present study, the depression was more common in
MS groups than in the stroke or healthy subjects. Epidemiological
studies reported that depression is common in MS with annual
prevalence rates as high as 20% and a lifetime prevalence of up to
50% (60–62), which is approximately three times higher than in
healthy people (61). Approximately one-third of all patients with
stroke experience depression symptoms and the prevalence only
slightly decreases within the first 2 years after stroke (63, 64). In our
study, the FKS did not correlate with BDI-II. The FKS is an impor-
tant tool for detecting motor fatigue objectively and independent
of the presence or absence of depression.
It may be speculative and beyond the scope of the present
investigation, but the motor fatigue in stroke and MS patients
probably suggests different underlying pathophysiological mech-
anisms. Ischemic lesions occur according to the all-or-nothing
principle: if oligemia causes an ischemic lesion, it results in a com-
plete lesion of the tissue finally ending up in the chronic stage as
a substantial cyst (simply speaking as a hole in the brain). Fatigue
in this case may be related to compensation or use of alterna-
tive, less efficient, or reorganized pathways. Inflammation in MS
might cause demyelination or partial impairment of neural path-
ways. Neuronal function may be partially preserved, but under
high demand or long or highly repetitive requirements function
might slowly decline. Further or additional compensation does
not seem to be possible, and it is unclear if this is due to loss
of K+ as suggested in the literature explaining the function of 4-
aminopyridine (65). Completely different pathomechanisms may
be related to inflammatory substances such as cytokines or tumor
necrosis factor alpha (TNF-α) (Hacken et al., this special issue) (8).
Increased cytokines, however, are not a prominent finding in the
liquor of chronic stroke patients, and hence fatigue is expected to
have a different pathomechnism in stroke. Different pathomech-
anisms of fatigue would require different treatment options (8,66).
For instance, compensation in stroke patients may be enhanced by
training, and electric failure in MS lesions may be ameliorated
by substances such as 4-aminopyridine or inhibitors of TNF-α
(67, 68).
Most standardized fatigue questionnaires are based on patients’
self-assessments and often used for rating fatigue symptoms.
However, because these questionnaires are based on the patients’
subjective impressions, they may be distorted because of an inaccu-
rate self-perception. Currently, most of the fatigue questionnaires
are disease specific and have been specifically developed to assess
fatigue in MS (29). Elbers et al. (23) recommended the FSMC for
the multidimensional assessment of fatigue in MS patients (23).
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In contrast, the FSS is the most commonly used instrument to
measure fatigue in stroke patients (69), which was also recom-
mended by Elbers et al. (23). Since most of the motor scores are
disease specific, it is not easy to compare the degree of impairment
in stroke and MS patients. For instance, the Motricity Index (70),
the Fugl-Meyer test (71), or Rivermead Motor Assessment (72)
are evaluated for stroke, whereas the application of the Expanded
Disability Status Scale (73) is restricted to MS, and there is no
common measure for both entities. To overcome this difficulty, we
used the Physical Functioning Scale of the SF-36 to assess daily
life motor activities and their restrictions. This allowed for some
rough comparison of motor impairment and disabilities in daily
life. Currently, there is a validated scale for fatigue in both MS and
stroke patients (74), which was not available at the time of data
collection.
The estimation error may occur in the clinical assessment of
the patient by physicians and physiotherapists. Some patients are
hard to classify into fatigue and non-fatigue groups based on
patient’s survey and traditional clinical tests carried out by physi-
cians and therapists. The results of the FKS largely agreed with the
results of the video analysis in MS patients. The physiotherapists
assigned videos of the beginning and end correctly in 80–85% of
MS patients. Such classification was difficult for stroke patients
and healthy subjects. In general, the MS patients have almost an
unremarkable gait pattern at the beginning of walking. In the state
of fatigue, the gait changed greatly. Thus, it can be clearly seen in
most cases. However, it depends on the experience of the physio-
therapist. In contrast to MS, the stroke patients had an impaired
gait pattern at the beginning of walking test. All stroke patients
had a hemiparesis and hence an abnormal gait pattern at both
time points. It is possible that the raters cannot be distinguishing
between the abnormal gait characteristics caused by the hemi-
paresis and those caused by motor fatigue. This could lead to
difficulties to assess the changes in gait pattern. Even if this evalu-
ation was very successful for these cases, the analysis is subjective
and depends on many factors and particularly on the therapists’
experience. These results emphasize the importance of an objec-
tive measure of motor fatigue that is independent of the subjective
assessment of a rater.
The FKS is an objective measure. As acknowledged above in
many cases, a neurologist can detect the presence of fatigue in
patients with MS using “classic” instruments. However, in some
cases, a physician cannot be sure of the diagnosis of the fatigue
syndrome, and in these cases, the FKS can be extremely helpful
for objectively measuring motor fatigue. The correct diagnosis
of fatigue is especially important when it is used as criterion
for early retirement emphasizing the relevance of this test. For
example, the most important differential diagnosis may be depres-
sion. In some instances, it may not be easy to disentangle both
phenomena. Treatment may be similar involving antidepressive
agents, increasing regular physical activity, acceptance of limita-
tions, energy conservation programs, etc. However, the patient
will feel more accepted and understood, if the therapist and
neurologist are able to discriminate, explain, and treat different
components of his complex symptom. Moreover, the FKS can be
used both for diagnosis and for the evaluation of the course of
treatment.
CONCLUSION
Using FKS, a new and objective tool for identifying and quantify-
ing motor fatigue, we found that fatigue was similarly pronounced
in both patient groups. We observed that a more severe walk-
ing impairment in stroke patients at baseline is not associated
with a pathologically higher FKS. The objective assessment of
motor fatigue via the FKS allows the comparison of motor fatigue
between stroke patients, MS patients, and healthy persons.
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